Archit Organosys Limited has delivered impressive financial performance for the third quarter of FY26, with the company's Board of Directors approving the unaudited financial results for the quarter and nine months ended December 31, 2025, during their meeting held on February 7, 2026.

Strong Quarterly Performance

The company demonstrated robust growth in Q3FY26, with significant improvements across all major financial parameters compared to the corresponding quarter of the previous year.

The quarter-on-quarter performance also showed positive momentum, with net profit increasing from ₹153.92 lakhs in Q2FY26 to ₹243.48 lakhs in Q3FY26, marking a 58.2% sequential growth.

Nine-Month Performance Highlights

The company's nine-month performance for the period ended December 31, 2025, reflected sustained growth momentum across key metrics.

Operational and Cost Structure Analysis

The company's expense management showed mixed trends during Q3FY26. While cost of materials consumed increased to ₹1,485.34 lakhs from ₹919.56 lakhs in Q3FY25, this was offset by improved operational efficiency. Employee benefit expenses decreased to ₹181.47 lakhs compared to ₹216.25 lakhs in the corresponding quarter last year. Finance costs rose to ₹55.56 lakhs from ₹47.18 lakhs, while depreciation remained relatively stable at ₹151.74 lakhs.

Regulatory Compliance and Business Segment

Archit Organosys operates in a single segment focused on chemicals and organics, which is considered the company's only reportable business segment. The company has implemented provisions related to the New Labour Codes that became effective on November 21, 2025, recognizing defined benefit obligations based on management's assessment. The company continues monitoring the finalization of Central and State Rules and clarifications from the Government regarding various aspects of the New Labour Codes.

Financial Position and Shareholder Returns

The company maintained a stable capital structure with paid-up equity share capital of ₹2,052.07 lakhs, consisting of shares with a face value of ₹10 each. The strong earnings performance translated into improved earnings per share, with both basic and diluted EPS reaching ₹1.19 for Q3FY26 compared to ₹0.49 in the corresponding quarter of the previous year. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors completing the required limited review under SEBI regulations.

Archit Organosys Limited has disclosed a substantial acquisition by promoter Suchit Kandar Pamin under SEBI regulations. The transaction, completed on December 15, 2025, involved the acquisition of equity shares through open market purchase, resulting in an increase in the promoter's shareholding percentage.

Transaction Details

The acquisition involved a small but significant transaction for regulatory disclosure purposes. The following table summarizes the key transaction parameters:

Shareholding Pattern Changes

The acquisition has resulted in a marginal increase in the promoter's stake in the company. The shareholding pattern before and after the transaction shows the following changes:

Company Capital Structure

Archit Organosys Limited maintains a stable capital structure with no changes resulting from this transaction. The company's equity share capital details are as follows:

Persons Acting in Concert

The disclosure identifies several persons acting in concert (PAC) with the acquirer, including family members who are part of the promoter group:

• Kandarp Amin
• Archana Amin
• Archit Amin
• Shimoli Amin
• Manini Amin

Regulatory Compliance

The transaction has been disclosed in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure confirms that no encumbrances, voting rights other than shares, or convertible securities were involved in this transaction. The acquirer belongs to the promoter group, and the acquisition represents a straightforward equity share purchase through the open market mechanism.